Export financials
Fluidigm Corporation (FLDM)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.

Fluidigm Corporation Income Statement 2020-2011 | FLDM
Brief overview of profit and loss at Fluidigm Corporation
The conclusions below are based on five years of reported results. Revenue at Fluidigm Corporation moved from $115 million in 2015 to $138 million in 2020. The total change was +20.4%, with a CAGR of approximately 3.8%. Revenue was effectively stagnant over the period.
Gross profit was $68.1 million at the start and $83.3 million at the end of the period (+22.4%). At the margin level, the figure shifted from 59.4% to 60.3%. Gross profitability remained broadly stable.
The five-year EBITDA result moved by +7.7%: from −38 million dollars to −35.1 million dollars. EBITDA lagged revenue, showing weaker operating momentum. EBITDA margin moved from −33.1% to −25.4%. The increased EBITDA share is a positive sign.
Net income moved from −$53.3 million at the start to −$53 million at the end. Losses became smaller, but the business remains unprofitable.
The market value of the business moved from 193 million dollars to 481 million dollars, or +149.8%. Investor expectations increased faster than reported performance.
Overall conclusion
The financial profile remains mixed, with strengths and risks moving in different directions. The positive side is supported by higher operating efficiency, a steady final result and a stable gross margin. The weaker side of the profile includes limited revenue growth and a low EBITDA margin. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement Fluidigm Corporation
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
481 M | 262 M | 340 M | 216 M | 175 M | 193 M | 1.07 B | 1.14 B | 361 M | 264 M |
Shares |
74.3 M | 66.8 M | 39.7 M | 33 M | 29 M | 28.7 M | 27.8 M | 25.5 M | 22.1 M | 17.8 M |
Net Income |
-53 M | -64.8 M | -59 M | -60.5 M | -76 M | -53.3 M | -52.8 M | -16.5 M | -19 M | -22.5 M |
Revenue |
138 M | 117 M | 113 M | 102 M | 104 M | 115 M | 116 M | 71.2 M | 52.3 M | 42.9 M |
EBITDA |
-35.1 M | -36 M | -31.6 M | -39.8 M | -55.3 M | -38 M | -27.3 M | -14.8 M | -15.9 M | -14.5 M |
Operating Expenses |
134 M | 116 M | 110 M | 110 M | 132 M | 122 M | 115 M | 68.4 M | 55.1 M | 45.2 M |
General and Administrative Expenses |
97.9 M | 84.5 M | 79.8 M | 79.5 M | 93.2 M | 83 M | 71.3 M | 48.4 M | 38.5 M | 31.3 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Fluidigm Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Anixa Biosciences
ANIX
|
$ 2.81 | 1.63 % | $ 91.2 K | ||
|
Biodesix
BDSX
|
$ 27.49 | 1.95 % | $ 208 M | ||
|
Biomerica
BMRA
|
$ 2.4 | 5.96 % | $ 7 M | ||
|
BioNano Genomics
BNGO
|
$ 1.35 | 10.66 % | $ 7.35 M | ||
|
Burning Rock Biotech Limited
BNR
|
$ 11.67 | 5.68 % | $ 123 M | ||
|
Bioventus
BVS
|
$ 13.22 | 1.85 % | $ 881 M | ||
|
CareDx, Inc
CDNA
|
$ 52.37 | 4.21 % | $ 2.79 B | ||
|
Celcuity
CELC
|
$ 83.55 | 0.12 % | $ 3.91 B | ||
|
Co-Diagnostics
CODX
|
$ 1.14 | 1.79 % | $ 1.52 M | ||
|
Charles River Laboratories International
CRL
|
$ 269.48 | 0.06 % | $ 13.4 B | ||
|
Castle Biosciences
CSTL
|
$ 33.22 | 2.74 % | $ 963 M | ||
|
Quest Diagnostics Incorporated
DGX
|
$ 239.32 | 1.83 % | $ 26.6 B | ||
|
Danaher Corporation
DHR
|
$ 202.7 | 1.28 % | $ 144 B | ||
|
DarioHealth Corp.
DRIO
|
$ 7.1 | 2.31 % | $ 28.3 M | ||
|
Fulgent Genetics
FLGT
|
$ 20.56 | 0.54 % | $ 633 M | ||
|
Guardant Health
GH
|
$ 165.87 | 5.39 % | $ 20.8 B | ||
|
ICON Public Limited Company
ICLR
|
$ 169.34 | 0.02 % | $ 13.3 B | ||
|
IDEXX Laboratories
IDXX
|
$ 509.72 | 0.99 % | $ 41 B | ||
|
Illumina
ILMN
|
$ 207.94 | 0.72 % | $ 32.2 B | ||
|
IQVIA Holdings
IQV
|
$ 264.81 | 1.16 % | $ 45.5 B | ||
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M | ||
|
Laboratory Corporation of America Holdings
LH
|
$ 314.56 | 0.95 % | $ 26.2 B | ||
|
Lantheus Holdings
LNTH
|
$ 100.27 | 0.02 % | $ 6.77 B | ||
|
Medpace Holdings
MEDP
|
$ 591.17 | 0.62 % | $ 17.1 B | ||
|
Mettler-Toledo International
MTD
|
$ 1 287.94 | 1.01 % | $ 26.5 B | ||
|
Myriad Genetics
MYGN
|
$ 3.74 | 9.36 % | $ 346 M | ||
|
ENDRA Life Sciences
NDRA
|
$ 5.68 | 0.98 % | $ 4.47 M | ||
|
NeoGenomics
NEO
|
$ 18.27 | 5.51 % | $ 2.34 B | ||
|
Neogen Corporation
NEOG
|
$ 11.87 | 0.72 % | $ 2.58 B | ||
|
National Research Corporation
NRC
|
$ 22.14 | 4.83 % | $ 496 M | ||
|
Natera
NTRA
|
$ 339.13 | 3.1 % | $ 46.4 B | ||
|
OPKO Health
OPK
|
$ 1.55 | 0.38 % | $ 1.16 B | ||
|
Pacific Biosciences of California
PACB
|
$ 1.36 | 4.23 % | $ 408 M | ||
|
Koninklijke Philips N.V.
PHG
|
$ 25.15 | 2.28 % | $ 23.8 B | ||
|
Personalis
PSNL
|
$ 16.3 | 0.52 % | $ 1.45 B | ||
|
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | ||
|
Senseonics Holdings
SENS
|
$ 8.88 | 1.95 % | $ 371 M | ||
|
Neuronetics
STIM
|
$ 2.89 | 5.61 % | $ 191 M | ||
|
Thermo Fisher Scientific
TMO
|
$ 611.62 | 0.3 % | $ 231 B | ||
|
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | ||
|
Twist Bioscience Corporation
TWST
|
$ 136.05 | 6.94 % | $ 8.14 B | ||
|
VolitionRx Limited
VNRX
|
$ 0.31 | 0.34 % | $ 39 M | ||
|
Waters Corporation
WAT
|
$ 407.54 | 1.67 % | $ 24.3 B | ||
|
Heska Corporation
HSKA
|
- | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | ||
|
Syneos Health
SYNH
|
- | - | $ 4.46 B | ||
|
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | ||
|
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | ||
|
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M | ||
|
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M |